Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Board Member Padou Passes Away; Invitrogen Loses Two VPs; Wellis Is New GenVault CEO; Nelles Tapped for R&D VP at XDx; and Others

NEW YORK (GenomeWeb News) - Bio-Rad reported last week that board member Philip Padou has died at the age of 72.
 
Padou joined Bio-Rad’s Board in 1980, and he was VP and CFO of Ozier Perry and Associates until his retirement in 1991.
 
David Schwartz, chairman of Bio-Rad’s board, said in a statement that Padou was “a dedicated and valuable member” of the board.
 
The company said it will begin seeking a replacement for Padou as soon as possible.
 

 
Invitrogen disclosed in an SEC filing last week that senior VP of commercial operations Ben Bulkley and finance and principal accounting officer John Radak will leave the company at the end of January.
 
Radak is taking on the role of CFO at Quidel, a developer of diagnostics for disease, at the beginning of February. 
 
Bulkley will be replaced by current GM and VP of European operations Bernd Brust. Brust will be responsible for sales strategies, customer relations, and identifying avenues for customer growth.
 
Radak will be replaced by Kelli Richard, who has served as corporate controller at Invitrogen and as VP and controller at Gateway.
 

 
David Wellis was appointed as CEO of GenVault in mid-December, the company said last week.
 
Wellis was promoted from senior VP of marketing and sales, a position he held since December 2004. He joined the firm in 2002 as VP of business development and marketing.
 
Before joining GenVault, Wellis was VP of functional genomics at Axon Instruments.
 

 
Molecular diagnostics company XDx has appointed Mitchell Nelles to the post of VP of R&D and technical operations.
 
Nelles will develop the company’s products and help expand its AlloMap molecular expression test.
 
Nelles recently worked as VP of North American R&D at bioMerieux, and previously was VP of R&D at TriPath Oncology, where he led development of molecular products for cancer diagnostics.
 

 
Former Sirna Therapeutics president and CEO Howard Robin has been hired to serve as president and chairman at biopharmaceutical company Nektar.
 
Robin was at Sirna for five years, where he oversaw the company's re-launch and its $1.1 billion acquisition by Merck. Robin also served as a VP and GM at Berlex Labs.
 

 
Cancer profiling company AviaraDx has hired Carol Berry to fill the position of VP of sales.
 
Berry’s was previously responsible for North American sales and marketing at Ciphergen Biosystems, and also held sales positions at Dynacare, Cerner, and Roche.
 

 
Ben Bowen has been named VP of business development at Biolog.
 
In this position, Bowen will oversee the launch the company’s mammalian cell Phenotype Microarray line.
 
Before coming to Biolog, Bowen was VP of discovery and research at Lynx Therapeutics and also worked at Pioneer Hi-Bred, now a subsidiary of DuPont, where he was responsible for large-scale genomics efforts in the agriculture and biotech industry. 
 

 
Sequence analysis software company Gene-IT has hired Michael McManus as VP and general manager, the company said last week. McManus will handle corporate marketing, strategic alliances and product marketing, the company said. 
 
McManus previously was in charge of US development at the Biosciences Group at Fujitsu, and he had been a VP and COO at AnVil and a VP of marketing and business development at CambridgeSoft.
 

 
Molecular detection and analysis developer ForteBio has appointed William Albright as COO, the company said last week.
 
Albright previously served as COO and senior VP of finance and operations at Xenogen (now part of Caliper), where he oversaw a $30 million IPO. At ForteBio Albright will be responsible for handling finance issues, operations and raising capital.
 

 
RTI International said last week that Claude Hughes has joined as VP for the Partnership for Genomics and Molecular Epidemiology and as chief medical officer.     
 
In the position, Hughes will lead a team of researchers studying genomics, proteomics, chemoinformatics, social and economic genomics and measurement of gene and protein expression.
 
Before coming to RTI, Hughes was executive director of medical and scientific services at Quintiles and a medical and scientific director for the Quintiles-Solvay partnership.
 

 
Bioconvergence has expanded its business development and client services staff.
 
Steve Bryant has been named manager of business development and marketing. Bryant was formerly involved in the Bloomington Life Science Partnership, where he held various positions, and he was a former staffer for US Senators Dick Lugar and Dan Coats.
 
The company has also named John Grove business development executive for California. Grove formerly owned and ran Grove BioPharma Consulting.
 
Janet Carminati has been named manager of client management. Carminati was recently director of business development and client management at Deltagen.
 

 
Rapid Micro Biosystems has hired Katherine Flagg for the new position of VP of business development, and has named her to be part of the company’s executive committee on long-term strategy.
 
In this position Flagg will oversee sales and business development for the company’s Growth Direct product.
 
Before coming to Rapid Micro, Flagg was a sales manager for BioVeris and Pharmacia.
 

 
Clinical biomarker development company Miraculins has hired Sandra Benson of Genesys Venture to serve as manager of investor relations.
 
Benson will work on investor strategies, communicating with shareholders and potential shareholders, media, and increasing market awareness. Miraculins said it has contracted GVI for a 12-month renewable agreement.
 

 
 
Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.